Source: American heart journal. Unidade: FM
Subjects: MORFINA, INFARTO DO MIOCÁRDIO, FÁRMACOS SINTÉTICOS
ABNT
CANTOR, Warren J et al. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial. American heart journal, v. 251, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2022.05.005. Acesso em: 03 set. 2024.APA
Cantor, W. J., Tan, M., Berwanger, O., Lavi, S., White, H. D., Nicolau, J. C., et al. (2022). Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial. American heart journal, 251, 1-12. doi:10.1016/j.ahj.2022.05.005NLM
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial [Internet]. American heart journal. 2022 ; 251 1-12.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.ahj.2022.05.005Vancouver
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial [Internet]. American heart journal. 2022 ; 251 1-12.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.ahj.2022.05.005